• In January 2026, UnitedHealth Group reported full-year 2025 results showing revenue rising to US$447.57 billion while net income and diluted EPS declined year on year, and issued 2026 guidance for revenue above US$439.00 billion, operating earnings above US$24.00 billion and EPS above US$17.10.
• At the same time, a proposed 0.09% Medicare Advantage rate increase for 2027 and plans to shrink Optum Health’s footprint highlighted how policy pressures and portfolio adjustments are reshaping UnitedHealth’s core earnings engine.
• With these developments and the minimal proposed Medicare Advantage rate increase, we’ll now explore what they mean for UnitedHealth Group’s investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 32 companies in the world exploring or producing it. Find the list for free.

What Is UnitedHealth Group's Investment Narrative?

To own UnitedHealth Group today, you have to believe its vertically integrated model can still compound earnings even as Medicare Advantage becomes less generous and more politicized. The latest results and 2026 guidance underline that revenue remains very large at about US$447.57 billion, but profit pressure is real, with net income and EPS down year on year and margins thinning. The proposed 0.09% Medicare Advantage rate increase for 2027, the stock’s near 20% single-day drop, and management’s decision to shrink Optum Health’s footprint and pause big deals collectively reset the near term catalysts: it is less about expansion and more about margin repair, pricing discipline, regulatory outcomes and execution on a “back to basics” plan. In that context, policy risk and a potential first revenue decline since 1989 now sit at the center of the story.

However, one risk in particular could catch shareholders off guard if they are not watching closely. Despite retreating, UnitedHealth Group's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Eighty Simply Wall St Community fair values span roughly US$308 to almost US$793 per share, reflecting sharply different expectations at a time when Medicare policy decisions and margin repair efforts are front and center for UnitedHealth’s performance debate.

Explore 80 other fair value estimates on UnitedHealth Group - why the stock might be worth over 2x more than the current price!

Build Your Own UnitedHealth Group Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your UnitedHealth Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free UnitedHealth Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate UnitedHealth Group's overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Find companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.